You are here: Industry Insights > MS

News List

FDA and EMA accept licence applications for multiple sclerosis treatment europeanpharmaceuticalreview
March 04, 2020
The FDA and EMA have accepted licence applications for ofatumumab, a novel B-cell therapy for patients with relapsing forms of multiple sclerosis (RMS).
2011 to 2017 Saw Increase in Spending on DMTs for MS drugs
January 16, 2020
From 2011 to 2017, there was an increase in gross annual expenditures on multiple sclerosis (MS) disease-modifying therapies (DMTs), with increased spending mainly driven by increases in per-prescription costs, according to a study published online Januar
MS treatment trial to compare stem cell transplantation to biologic drugs europeanpharmaceuticalreview
January 14, 2020
The BEAT-MS trial aims to compare the experimental autologous hematopoietic stem cell transplantation (AHSCT) therapy to the best available biologic therapies for multiple sclerosis (MS).
Marijuana Use for MS Tied to Legal Permissiveness drugs
December 30, 2019
Cannabis use among patients with multiple sclerosis (MS) is more likely where cannabis laws are more permissive, according to a study published in the February issue of Multiple Sclerosis and Related Disorders.
Breastfeeding May Protect Against Postpartum Relapses in MS drugs
December 19, 2019
Breastfeeding may be protective against postpartum relapses in multiple sclerosis (MS), according to a review and meta-analysis published online in JAMA Neurology.
MetP Pharma Receives US Patent for Drug Therapy of Demyelinating and Neuroinflammatory Diseases such as Multiple Sclerosis b3cnewswire
December 18, 2019
MetP® Pharma AG announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for ...
Breastfeeding May Bring Added Bonus for Women With MS drugs
December 12, 2019
Women with multiple sclerosis often find that their symptoms ease during pregnancy. And evidence is growing that breastfeeding might have a similar benefit.
Multiple sclerosis drug market predicted to reach $32.9bn by 2028 europeanpharmaceuticalreview
December 12, 2019
Driven by the launch of various pipeline agents, a new report has projected that the multiple sclerosis therapeutics market will reach $32.9 billion in 2028.
The gut may be involved in the development of multiple sclerosis worldpharmanews
December 09, 2019
It is incompletely understood which factors in patients with multiple sclerosis (MS) act as a trigger for the immune system to attack the brain and spinal cord.
AAN Issues Guideline on Vaccines and MS americanpharmaceuticalreview
September 03, 2019
According to guidelines developed by the American Academy of Neurology (AAN), people with MS should receive recommended vaccinations, including yearly flu shots.

Previous page 1 2 3 4 5 6 7 8 9 Next page